SS31 peptide claims on TikTok: what the science says

What did @sethkardos actually say?

The creator describes SS-31 as a "mitochondrial peptide" he's been self-experimenting with, reporting he's been "feeling awesome" since starting it. He cites a dosing range of 500 micrograms on the low end to 40 milligrams per day on the high end, noting that clinical studies at the higher dose were conducted in patients with kidney failure. He frames the lower dose as potentially sufficient for healthy people seeking a "mitochondrial boost."

To his credit, he doesn't claim SS-31 treats or cures anything specific. He's also upfront that he's experimenting on himself and soliciting other people's experiences rather than issuing instructions. That's a more honest framing than most peptide content on this platform. But "feeling awesome" is not data, and the dosing discussion has some real problems worth unpacking.

Does the science back this up?

SS-31, also called elamipretide, does have a legitimate research foundation, though it's nowhere near proven for healthy human use. The science is real but early.

SS-31 is a tetrapeptide that targets cardiolipin on the inner mitochondrial membrane, reducing oxidative stress and supporting ATP production. Szeto and colleagues have published extensively on its mechanism since the mid-2000s. The most clinically advanced work involves heart failure and kidney disease. A Phase II trial by Daubert et al. (2017, JACC: Basic to Translational Science) tested elamipretide in patients with heart failure with preserved ejection fraction and found modest improvements in cardiac function at doses far below 40 mg/day. The PROGRESS-HF trial explored it in heart failure with reduced ejection fraction but results were mixed.

The 40 mg/day figure the creator cites does appear in some clinical protocols for acute kidney injury and ischemia-reperfusion injury, but these are intravenous or subcutaneous doses in sick patients under medical supervision. Extrapolating that to healthy self-experimenters is a meaningful leap the creator doesn't adequately flag.

Evidence for SS-31 in healthy humans as a longevity or performance compound is essentially nonexistent in peer-reviewed literature right now.

What did they get wrong (or right)?

The creator gets the basic mechanism broadly right. SS-31 does act at the mitochondrial level, and cardiolipin targeting is well-documented in the literature. Calling it a "mitochondrial peptide" is a fair shorthand.

Where things go sideways is the dosing framing. Saying you can take "as low as 500 micrograms" and still get benefit "if you're overall healthy" presents an untested assumption as a near-certainty. There are no published human trials establishing a minimum effective dose for healthy subjects because no such trials exist. That 500 mcg figure appears to circulate in biohacker communities and peptide forums, not clinical literature.

The comparison between clinical trial doses (used in kidney failure patients) and doses for healthy people is also under-explained. Sick patients in controlled trials have monitored renal function, IV administration, and medical oversight. Self-experimenting with subcutaneous SS-31 at home is a categorically different situation, and the creator treats it as a simple sliding scale rather than a fundamentally different risk context.

Bouncing "back and forth" between low and high doses without a rationale is not research. It's experimentation without controls, and presenting it as "personal research" gives it more credibility than it deserves.

What should you actually know?

SS-31 is a genuinely interesting compound in early-stage research. That's worth saying plainly. Animal studies show real effects on mitochondrial function in aging models. Bharat et al. (2022, Aging Cell) demonstrated improved cardiac function in aged mice. The human data, however, is concentrated in diseased populations and the results are mixed even there.

For healthy adults, there is no established safe dose, no established effective dose, and no long-term human safety data. The compound is not FDA-approved for any use as of 2024. Elamipretide (the pharmaceutical-grade version) failed to gain approval in its most studied indication. Compounded SS-31 available through peptide suppliers has no standardized purity verification.

• Do not interpret clinical trial dosing ranges as guidance for self-administration.
• "Feeling awesome" after starting a new compound is a notoriously unreliable signal, placebo response is real and well-documented.
• Anyone considering SS-31 should have that conversation with a physician who can assess kidney function, cardiovascular status, and actual risk profile.
• The peptide is not a proven treatment for mitochondrial disease or any other condition.

The creator asks if viewers have experimented with it. That's a reasonable community question, but crowdsourcing dosing information for an unapproved, understudied peptide from TikTok comments is not a substitute for medical guidance.